Literature DB >> 1483495

Effect of propranolol on urinary prostaglandin E2 excretion and renal interlobar arterial blood flow after furosemide administration in patients with hepatic cirrhosis.

N Ljubicić1, A Bilić, V Plavsić.   

Abstract

The effect of propranolol on furosemide-stimulated urinary prostaglandin E2 (PGE2) excretion and renal blood flow was evaluated in 12 patients with alcoholic liver cirrhosis. Plasma and urine were collected before and 60 min after furosemide 20 mgI with or without propranolol pretreatment, and plasma renin activity (PRA), plasma aldosterone concentration (PAC), urinary excretion of PGE2 and sodium were determined. The renal interlobar arterial Pulsatility Index (PI), as an index of resistance to blood flow, was also determined before and 60 min after furosemide administration with and without propranolol pretreatment, by using a duplex Doppler ultrasound (Hitachi EUB 565). Urine volume and sodium excretion after furosemide administration were not influenced by the propranolol pretreatment. Furosemide administration significantly increased urinary PGE2 excretion, PRA and PAC, and these effects were significantly reduced by propranolol. Furosemide administration with or without propranolol significantly reduced renal interlobar arterial PI, the average reduction in PI being significantly lower after furosemide administration with propranolol pretreatment. The results demonstrate that propranolol pretreatment significantly influenced the furosemide-induced increase in urinary PGE2 excretion and renal interlobar arterial blood flow in cirrhotic patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1483495     DOI: 10.1007/bf02285102

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  16 in total

1.  Inhibition of the renin-aldosterone response to furosemide by indomethacin.

Authors:  S Y Tan; P J Mulrow
Journal:  J Clin Endocrinol Metab       Date:  1977-07       Impact factor: 5.958

2.  Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases.

Authors:  F R Bühler; J H Laragh; L Baer; E D Vaughan; H R Brunner
Journal:  N Engl J Med       Date:  1972-12-14       Impact factor: 91.245

Review 3.  The physical principles of Doppler and spectral analysis.

Authors:  P N Burns
Journal:  J Clin Ultrasound       Date:  1987 Nov-Dec       Impact factor: 0.910

4.  Blood flow in deep abdominal and pelvic vessels: ultrasonic pulsed-Doppler analysis.

Authors:  K J Taylor; P N Burns; J P Woodcock; P N Wells
Journal:  Radiology       Date:  1985-02       Impact factor: 11.105

5.  A randomized controlled study of propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: a final report.

Authors:  D Lebrec; T Poynard; J Bernuau; E Bercoff; O Nouel; J P Capron; R Poupon; M Bouvry; B Rueff; J P Benhamou
Journal:  Hepatology       Date:  1984 May-Jun       Impact factor: 17.425

6.  Effects of propranolol on renal blood flow and renal function in patients with cirrhosis.

Authors:  C Bataille; E Bercoff; E A Pariente; D Valla; D Lebrec
Journal:  Gastroenterology       Date:  1984-01       Impact factor: 22.682

7.  Noninvasive characterization of renal artery blood flow.

Authors:  E R Greene; M D Venters; P S Avasthi; R L Conn; R W Jahnke
Journal:  Kidney Int       Date:  1981-10       Impact factor: 10.612

8.  The kallikrein-kinin system and prostaglandins in the kidney: their relation to forosemide-induced diuresis and to the renin-angiotensin-aldosterone system in man.

Authors:  K Abe; N Irokawa; M Yasujima; M Seino; S Chiba; Y Sakurai; K Yoshinaga; T Saito
Journal:  Circ Res       Date:  1978-08       Impact factor: 17.367

9.  Radioimmunoassay measurement of prostaglandins E, A, and F in human plasma.

Authors:  B M Jaffe; H R Behrman; C W Parker
Journal:  J Clin Invest       Date:  1973-02       Impact factor: 14.808

10.  The effect of propranolol on urinary prostaglandin E2 after frusemide administration in healthy subjects.

Authors:  A Fujimura; H Kajiyama; A Ebihara
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

View more
  3 in total

1.  Hemodynamic effects of renin-angiotensin-aldosterone inhibitor and β-blocker combination therapy vs. β-blocker monotherapy for portal hypertension in cirrhosis: A meta-analysis.

Authors:  Jianrong Wang; Wenxia Lu; Jingjing Li; Rong Zhang; Yuqing Zhou; Qin Yin; Yuanyuan Zheng; Fan Wang; Yujing Xia; Kan Chen; Sainan Li; Tong Liu; Jie Lu; Yingqun Zhou; Chuan-Yong Guo
Journal:  Exp Ther Med       Date:  2017-03-09       Impact factor: 2.447

2.  Acute effect of propranolol and isosorbide-5-mononitrate administration on renal blood flow in cirrhotic patients.

Authors:  A J Stanley; I A Bouchier; P C Hayes
Journal:  Gut       Date:  1998-02       Impact factor: 23.059

Review 3.  Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions.

Authors:  F Pea; M Furlanut
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 5.577

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.